Prostatype Genomics AB (OSTO:PROGEN) Cash Flow from Operations: kr-23.80 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Prostatype Genomics AB Cash Flow from Operations?

Prostatype Genomics AB OSTO:PROGEN +1.03% Cash Flow from Operations is kr-23.80 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2025, Prostatype Genomics AB's Net Income From Continuing Operations was kr-20.58 Mil. Its Depreciation, Depletion and Amortization was kr1.09 Mil. Its Change In Working Capital was kr11.09 Mil. Its cash flow from deferred tax was kr0.00 Mil. Its Cash from Discontinued Operating Activities was kr0.00 Mil. Its Asset Impairment Charge was kr0.00 Mil. Its Stock Based Compensation was kr0.00 Mil. And its Cash Flow from Others was kr1.68 Mil. In all, Prostatype Genomics AB's Cash Flow from Operations for the six months ended in Dec. 2025 was kr-6.72 Mil.

Prostatype Genomics AB  (OSTO:PROGEN) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Prostatype Genomics AB's net income from continuing operations for the six months ended in Dec. 2025 was kr-20.58 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Prostatype Genomics AB's depreciation, depletion and amortization for the six months ended in Dec. 2025 was kr1.09 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Prostatype Genomics AB's change in working capital for the six months ended in Dec. 2025 was kr11.09 Mil. It means Prostatype Genomics AB's working capital increased by kr11.09 Mil from Jun. 2025 to Dec. 2025 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Prostatype Genomics AB's cash flow from deferred tax for the six months ended in Dec. 2025 was kr0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Prostatype Genomics AB's cash from discontinued operating Activities for the six months ended in Dec. 2025 was kr0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Prostatype Genomics AB's asset impairment charge for the six months ended in Dec. 2025 was kr0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Prostatype Genomics AB's stock based compensation for the six months ended in Dec. 2025 was kr0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Prostatype Genomics AB's cash flow from others for the six months ended in Dec. 2025 was kr1.68 Mil.

Prostatype Genomics AB Cash Flow from Operations Related Terms

Prostatype Genomics AB Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Cash Flow from Operations Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Operations
Get a 7-Day Free Trial -16.08 -27.69 -29.14 -44.71 -23.80

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.94 -23.21 -21.50 -17.08 -6.72

Prostatype Genomics AB Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Prostatype Genomics AB's Cash Flow from Operations for the fiscal year that ended in Dec. 2025 is calculated as:

Cash Flow from Operations(A: Dec. 2025 )
=Net Income From Continuing Operations+Depreciation, Depletion and Amortization+Change In Working Capital+Deferred Tax
=-44.503+2.187+12.983+0
+Cash from Discontinued Operating Activities+Asset Impairment Charge+Stock Based Compensation+Cash Flow from Others
+0+0+0+5.532
=-23.80

Prostatype Genomics AB's Cash Flow from Operations for the quarter that ended in Dec. 2025 is:

Cash Flow from Operations(Q: Dec. 2025 )
=Net Income From Continuing Operations+Depreciation, Depletion and Amortization+Change In Working Capital+Deferred Tax
=-20.583+1.092+11.091+0
+Cash from Discontinued Operating Activities+Asset Impairment Charge+Stock Based Compensation+Cash Flow from Others
+0+0+0+1.678
=-6.72

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-23.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of kr-23.80 Mil mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Cash Flow from Operations of kr-23.80 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Cash Flow from Operations too high?
Prostatype Genomics AB's current Cash Flow from Operations is kr-23.80 Mil.
How does Prostatype Genomics AB's Cash Flow from Operations compare to TMO and DHR?
Prostatype Genomics AB's Cash Flow from Operations of kr-23.80 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Medical Diagnostics & Research company?
A good Cash Flow from Operations depends on the Medical Diagnostics & Research industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Cash Flow from Operations is kr-23.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.10 — trading 145% above its estimated fair value. The current Cash Flow from Operations is kr-23.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Cash Flow from Operations is kr-23.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.